You are now leaving myCME and connecting to our educational partner. myCME does not control content, practices, or other policies of the site you are entering.
1.00 / AMA PRA Category 1 Credit(s)TM
This consensus statement on neurogenic detrusor overactivity (NDO) discusses the effect of NDO on the quality of life and overall health of patients with multiple sclerosis (MS) and spinal cord injury (SCI), identifies health care provider and patient barriers to care, describes best practices to screen for urinary dysfunction, and summarizes the panel’s recommendations for management of NDO in this patient population. Management strategies include antimuscarinic agents such as oxybutynin, onabotulinumtoxinA intradetrusor injection, sacral nerve stimulation, bladder augmentation or urinary diversion, and clean intermittent catheterization. Long-term follow-up of patients with NDO is important because changes in detrusor compliance and urodynamic patterns may occur over time.
This activity is designed for urologists, neurologists, physiatrists, and other health care professionals interested in or involved with the management of patients with multiple sclerosis or spinal cord injury who are at risk for neurogenic detrusor overactivity.
At the conclusion of this activity, participants should be able to:
In accordance with the disclosure policy of the Warren Alpert Medical School of Brown University as well as standards set forth by the Accreditation Council for Continuing Medical Education, all individuals in a position to control the content of a CME activity are required to disclose relevant financial relationships with commercial interests (within the past 12 months). Disclosures of this activity’s faculty and planning committee have been reviewed and all identified conflicts of interest, if applicable, have been resolved.
The planners, reviewers, editors, staff, or other members at Health and Wellness Education Partners and the Alpert Medical School CME Office who control content have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Warren Alpert Medical School of Brown University and Health and Wellness Education Partners. The Warren Alpert Medical School is accredited by the ACCME to provide continuing medical education for physicians.
The Warren Alpert Medical School designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is produced for educational purposes only. Content is provided by faculty who have been selected because of recognized expertise in their field. The opinions and recommendations expressed by the faculty whose input is included in this activity are their own. The use of the Warren Alpert Medical School of Brown University name implies oversight and review by the CME Office of educational content, format, design, and approach. Participants have the professional responsibility to review the complete prescribing information of specific drugs or combination of drugs including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients. The Warren Alpert School of Medicine of Brown University assumes no liability for the information herein.
Pamela I. Ellsworth, MD
University Urological Associates
2 Dudley Street, Suite 185, Providence, RI 02908
Phone: 1-401-421-0710, ext. 1323
Method of Participation/CME Credit
The Office of Continuing Medical Education (CME) is committed to protect the privacy of its members and customers. We collect only the information necessary to provide you with the services that you request and will keep personal information confidential.